On January 21, 2025, an expert team from Hongsheng Pharmaceutical, led by Chairman Wang Bingying and Director Ge Jingjing, visited our company. They held discussions with Bai Chen, the Chairman of MOMED Biotech, regarding the integration of traditional medicine and cutting - edge technology, as well as the potential for future cooperation.

On January 21, 2025, an expert team from Hongsheng Pharmaceutical, including its Chairman Wang Bingying and Director Ge Jingjing, visited MOMED Biotech for exchanges and guidance. Bai Chen, the Chairman of MOMED Biotech, warmly received them, accompanied by Zhu Xiaohong, the R & D Director, and An Ke, the Operations Director.

Led by Chairman Bai Chen, the Hongsheng Pharmaceutical delegation toured the R & D server room and work areas, gaining a preliminary understanding of MOMED Biotech's scientific research environment. 

Subsequently, the two sides held a panel discussion. During the meeting, they zeroed in on the cutting - edge hot topics in the pharmaceutical industry and shared their respective insights. With rich experience in traditional pharmaceutical manufacturing, Hongsheng Pharmaceutical affirmed MOMED Biotech's achievements in AI - driven new drug R & D, believing that AI technology could bring new opportunities to the industry. 

During the exchanges, both parties recognized the complementarity in technology and resources. Combining Hongsheng Pharmaceutical's traditional pharmaceutical manufacturing processes and market channels with MOMED Biotech's R & D capabilities is expected to achieve complementary advantages and synergistic effects in areas such as new drug R & D and pharmaceutical production process optimization. 

Both sides hold a positive attitude towards the prospects of cooperation. They look forward to achieving results in key areas such as chemical pharmaceuticals and biopharmaceutical innovation through collaboration, jointly solving industry challenges.